BYSI
- BeyondSpring Inc.
()
Overview
Company Summary
BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Established in 2013 and headquartered in New York City, the company leverages cutting-edge technology and scientific expertise to address unmet needs in the field of oncology.
BYSI specializes in the development of targeted immuno-oncology therapies, combining immunotherapies with chemotherapy in order to enhance their effectiveness. The company's primary focus is on the treatment of non-small cell lung cancer (NSCLC) and metastatic breast cancer (MBC), two prevalent and highly challenging forms of cancer.
BeyondSpring's most advanced product candidate is Plinabulin, a novel small molecule that has shown potential in activating the immune system to fight cancer cells. By stimulating the body's immune response, this therapy can enhance the efficacy of chemotherapy while minimizing its toxic side effects. Plinabulin is currently being evaluated in various clinical trials to assess its safety and efficacy across different cancer indications.
In addition to Plinabulin, BeyondSpring has a diverse pipeline of investigational drugs in various stages of development. These include BPI-7711, a targeted therapy for the treatment of gastrointestinal stromal tumors (GIST), and BPI-8200, a next-generation immunotherapy drug designed to overcome resistance to current treatments.
BYSI's mission is to improve the lives of cancer patients by developing innovative therapeutics that address unmet medical needs. Through their research and development efforts, the company aims to provide novel treatment options that can potentially offer better outcomes and improve the quality of life for cancer patients worldwide.